![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: INSL6 |
Gene summary for INSL6 |
![]() |
Gene information | Species | Human | Gene symbol | INSL6 | Gene ID | 11172 |
Gene name | insulin like 6 | |
Gene Alias | RIF1 | |
Cytomap | 9p24.1 | |
Gene Type | protein-coding | GO ID | GO:0007154 | UniProtAcc | Q9Y581 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
11172 | INSL6 | S014 | Human | Liver | HCC | 3.04e-33 | 8.42e-01 | 0.2254 |
11172 | INSL6 | S015 | Human | Liver | HCC | 5.98e-31 | 1.05e+00 | 0.2375 |
11172 | INSL6 | S016 | Human | Liver | HCC | 1.35e-41 | 9.76e-01 | 0.2243 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
INSL6 | SNV | Missense_Mutation | novel | c.409N>G | p.Ile137Val | p.I137V | Q9Y581 | protein_coding | tolerated(0.77) | benign(0.012) | TCGA-21-1080-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
INSL6 | SNV | Missense_Mutation | novel | c.253N>T | p.Thr85Ser | p.T85S | Q9Y581 | protein_coding | tolerated(0.28) | benign(0.023) | TCGA-33-AASI-01 | Lung | lung squamous cell carcinoma | Female | >=65 | I/II | Chemotherapy | taxotere | PD |
INSL6 | SNV | Missense_Mutation | c.104N>C | p.Arg35Thr | p.R35T | Q9Y581 | protein_coding | deleterious(0.03) | possibly_damaging(0.863) | TCGA-58-8391-01 | Lung | lung squamous cell carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | PD | |
INSL6 | SNV | Missense_Mutation | rs747730569 | c.302N>T | p.Trp101Leu | p.W101L | Q9Y581 | protein_coding | tolerated(0.66) | benign(0) | TCGA-CV-7100-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | III/IV | Unknown | Unknown | PD |
INSL6 | SNV | Missense_Mutation | c.352N>A | p.Asp118Asn | p.D118N | Q9Y581 | protein_coding | tolerated(0.12) | benign(0.015) | TCGA-CV-7568-01 | Oral cavity | head & neck squamous cell carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
INSL6 | SNV | Missense_Mutation | c.53G>A | p.Arg18Gln | p.R18Q | Q9Y581 | protein_coding | tolerated(0.34) | possibly_damaging(0.511) | TCGA-P3-A6T3-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | cisplatin | PD | |
INSL6 | SNV | Missense_Mutation | rs758608116 | c.8N>A | p.Arg3Gln | p.R3Q | Q9Y581 | protein_coding | tolerated(0.24) | benign(0.015) | TCGA-BR-4363-01 | Stomach | stomach adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
INSL6 | SNV | Missense_Mutation | c.451N>A | p.Arg151Ser | p.R151S | Q9Y581 | protein_coding | tolerated(0.88) | benign(0) | TCGA-CD-8529-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | epirubicin | CR | |
INSL6 | SNV | Missense_Mutation | c.188N>T | p.Arg63Leu | p.R63L | Q9Y581 | protein_coding | deleterious(0.04) | benign(0.148) | TCGA-CD-A4MG-01 | Stomach | stomach adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |